I
Israth Jahan Tuhin
Researcher at East China Normal University
Publications - 4
Citations - 26
Israth Jahan Tuhin is an academic researcher from East China Normal University. The author has contributed to research in topics: Immunotherapy & Chimeric antigen receptor. The author has an hindex of 1, co-authored 2 publications receiving 2 citations.
Papers
More filters
Journal ArticleDOI
Emerging role of RNA interference in immune cells engineering and its therapeutic synergism in immunotherapy.
Masuma Akter Monty,Ariful Islam,Xu Nan,Jingwen Tan,Israth Jahan Tuhin,Xiaowen Tang,Miao Miao,Depei Wu,Lei Yu +8 more
TL;DR: RNAi effectors (e.g., siRNA, shRNA, and miRNA) can efficiently trigger the silencing of specific genes, and its genomic alteration functions allowed to pursue clinical trials in distinct areas, including infectious diseases, neurodegenerative disorders, and cancer as discussed by the authors.
Journal ArticleDOI
Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody
Jing Ye,Y. Jia,Israth Jahan Tuhin,Jingwen Tan,Masuma Akter Monty,Nan Xu,Liqing Kang,Minghao Li,Xiaoyan Lou,Mei-Liang Zhou,Xiaoyan Fang,Jiaqi Shao,Hongjia Zhu,Zhiqiang Yan,Lei Yu +14 more
TL;DR: In this article , a new strategy of blocking the CD7 antigen on the T cell surface with a recombinant anti-CD7 antibody was proposed to obtain a sufficient amount of CD7-targeting CAR-T cells for T cell acute lymphoblastic leukemia (T-ALL) treatment.
Journal ArticleDOI
Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells
Jingwen Tan,Yu-qing Jia,Mei-Liang Zhou,Chengcheng Fu,Israth Jahan Tuhin,Jing Ye,Masuma Akter Monty,Nan Xu,Liqing Kang,Minghao Li,Jiaqi Shao,Xiaoyan Fang,Hongjia Zhu,Lingzhi Yan,Changju Qu,Shengli Xue,Zhongmin Jin,Suning Chen,Haiwen Huang,Yan Xu,Jia Chen,Miao Miao,Xiaowen Tang,Caixia Li,Zhiqiang Yan,Depei Wu,Lei Yu +26 more
TL;DR: In this article , a series of BCMA-targeting second-generation CAR constructs containing CD28, 41BB, and OX40 molecules were designed and constructed to identify the costimulatory domains most favorable for persistence.
Journal ArticleDOI
Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments.
TL;DR: The local administration of Ad5 vectors encoding IL17A-neutralizing antibody fragments provides a new option for HCC immunotherapy and suggests that IL 17A might promote HCC growth by enhancing the invasion and migration ability of hepatoma cells.